Hologic
- Home ›
- US ›
- Healthcare
Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The last earnings update was 45 days ago. More info.
Add to Portfolio Compare Print
HOLX Share Price and Events
7 Day Returns
1 Year Returns
HOLX Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Hologic (HOLX) | 1.8% | 6.1% | 0.4% | 18.3% | 41.5% | 86.9% |
| US Medical Equipment | 0.7% | 5.3% | 1.2% | 12.2% | 63.1% | 94.2% |
| US Market | 0.5% | 0.2% | 1.1% | 0.8% | 37.4% | 37.5% |
1 Year Return vs Industry and Market
- HOLX outperformed the Medical Equipment industry which returned 12.2% over the past year.
- HOLX outperformed the Market in United States of America which returned 0.8% over the past year.
HOLX Value
Is Hologic undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Hologic
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Hologic.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 19 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.8% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Medical Equipment Unlevered Beta | Simply Wall St/ S&P Global | 0.85 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.852 (1 + (1- 21%) (24.43%)) |
1.011 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.01 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.011 * 5.96%) |
8.75% |
Discounted Cash Flow Calculation for NasdaqGS:HOLX using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Hologic is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 8.75%) |
|
|---|---|---|---|
| 2019 | 765.50 | Analyst x2 | 703.89 |
| 2020 | 846.00 | Analyst x3 | 715.30 |
| 2021 | 858.72 | Analyst x2 | 667.62 |
| 2022 | 1,005.51 | Analyst x1 | 718.82 |
| 2023 | 1,039.81 | Analyst x1 | 683.50 |
| 2024 | 1,072.74 | Est @ 3.17% | 648.40 |
| 2025 | 1,105.32 | Est @ 3.04% | 614.32 |
| 2026 | 1,137.86 | Est @ 2.94% | 581.50 |
| 2027 | 1,170.63 | Est @ 2.88% | 550.10 |
| 2028 | 1,203.82 | Est @ 2.84% | 520.17 |
| Present value of next 10 years cash flows | $6,403.61 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $1,203.82 × (1 + 2.73%) ÷ (8.75% – 2.73%) |
$20,532.03 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $20,532.03 ÷ (1 + 8.75%)10 |
$8,871.79 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $6,403.61 + $8,871.79 |
$15,275.40 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $15,275.40 / 268.05 |
$56.99 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $56.99 |
| Current discount | Discount to share price of
$47.84
= -1 x ($47.84 - $56.99) / $56.99 |
16.1% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Hologic's share price is below the future cash flow value, but not at a moderate discount (< 20%).
- Hologic's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Hologic's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Hologic's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-30) in USD | $-0.04 |
| NasdaqGS:HOLX Share Price ** | NasdaqGS (2019-06-14) in USD | $47.84 |
| United States of America Medical Equipment Industry PE Ratio | Median Figure of 64 Publicly-Listed Medical Equipment Companies | 40.75x |
| United States of America Market PE Ratio | Median Figure of 3,091 Publicly-Listed Companies | 17.68x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Hologic.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:HOLX Share Price ÷ EPS (both in USD) = 47.84 ÷ -0.04 |
-1225.66x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Hologic is loss making, we can't compare its value to the US Medical Equipment industry average.
- Hologic is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Hologic's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -1225.66x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts |
48.4%per year |
| United States of America Medical Equipment Industry PEG Ratio | Median Figure of 55 Publicly-Listed Medical Equipment Companies | 2.19x |
| United States of America Market PEG Ratio | Median Figure of 2,125 Publicly-Listed Companies | 1.52x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Hologic, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Hologic's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-30) in USD | $8.06 |
| NasdaqGS:HOLX Share Price * | NasdaqGS (2019-06-14) in USD | $47.84 |
| United States of America Medical Equipment Industry PB Ratio | Median Figure of 183 Publicly-Listed Medical Equipment Companies | 4.36x |
| United States of America Market PB Ratio | Median Figure of 5,244 Publicly-Listed Companies | 1.79x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:HOLX Share Price ÷ Book Value per Share (both in USD) = 47.84 ÷ 8.06 |
5.94x |
* Primary Listing of Hologic.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Hologic is overvalued based on assets compared to the US Medical Equipment industry average.
Value checks
We assess Hologic's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Hologic has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
HOLX Future Performance
How is Hologic expected to perform in the next 1 to 3 years based on estimates from 19 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Hologic's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Hologic's earnings growth is expected to exceed the United States of America market average.
- Hologic's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:HOLX Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts | 48.4% |
| NasdaqGS:HOLX Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 19 Analysts | 3.5% |
| United States of America Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 21.9% |
| United States of America Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 7.9% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.9% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 19 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-09-30 | 3,837 | 706 | 2 | |
| 2022-09-30 | 3,703 | 569 | 3 | |
| 2021-09-30 | 3,578 | 911 | 504 | 12 |
| 2020-09-30 | 3,458 | 879 | 420 | 19 |
| 2019-09-30 | 3,337 | 608 | 29 | 18 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-30 | 3,287 | 705 | -11 |
| 2018-12-29 | 3,258 | 668 | -419 |
| 2018-09-29 | 3,218 | 733 | -111 |
| 2018-06-30 | 3,207 | 667 | -79 |
| 2018-03-31 | 3,189 | 21 | -133 |
| 2017-12-30 | 3,116 | 8 | 1,076 |
| 2017-09-30 | 3,059 | 8 | 756 |
| 2017-07-01 | 2,983 | 70 | 765 |
| 2017-04-01 | 2,894 | 729 | 790 |
| 2016-12-31 | 2,872 | 796 | 332 |
| 2016-09-24 | 2,833 | 798 | 331 |
| 2016-06-25 | 2,809 | 802 | 264 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 19 Analyst Estimates (S&P Global) | See Below |
All data from Hologic Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-09-30 | ||||
| 2022-09-30 | ||||
| 2021-09-30 | 2.09 | 2.66 | 1.85 | 5.00 |
| 2020-09-30 | 1.60 | 1.94 | 1.16 | 7.00 |
| 2019-09-30 | 0.10 | 0.15 | 0.07 | 7.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-30 | -0.04 |
| 2018-12-29 | -1.53 |
| 2018-09-29 | -0.40 |
| 2018-06-30 | -0.29 |
| 2018-03-31 | -0.48 |
| 2017-12-30 | 3.85 |
| 2017-09-30 | 2.70 |
| 2017-07-01 | 2.74 |
| 2017-04-01 | 2.84 |
| 2016-12-31 | 1.19 |
| 2016-09-24 | 1.18 |
| 2016-06-25 | 0.94 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Hologic's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Hologic has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
HOLX Past Performance
How has Hologic performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Hologic does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Hologic's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Hologic's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
All data from Hologic Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-30 | 3,286.60 | -10.60 | 881.70 | 217.60 |
| 2018-12-29 | 3,257.50 | -419.40 | 883.10 | 217.10 |
| 2018-09-29 | 3,217.90 | -111.30 | 875.90 | 218.70 |
| 2018-06-30 | 3,207.40 | -79.10 | 866.00 | 226.50 |
| 2018-03-31 | 3,189.40 | -132.50 | 853.00 | 234.60 |
| 2017-12-30 | 3,115.50 | 1,075.70 | 837.50 | 233.20 |
| 2017-09-30 | 3,058.80 | 755.50 | 799.90 | 232.80 |
| 2017-07-01 | 2,982.80 | 764.90 | 764.20 | 234.80 |
| 2017-04-01 | 2,894.10 | 790.30 | 721.20 | 231.10 |
| 2016-12-31 | 2,871.90 | 332.40 | 685.80 | 234.80 |
| 2016-09-24 | 2,832.70 | 330.80 | 676.40 | 232.10 |
| 2016-06-25 | 2,808.60 | 263.80 | 671.20 | 223.30 |
| 2016-03-26 | 2,785.10 | 208.40 | 667.10 | 220.50 |
| 2015-12-26 | 2,747.40 | 187.30 | 647.10 | 214.60 |
| 2015-09-26 | 2,705.00 | 131.60 | 624.00 | 214.90 |
| 2015-06-27 | 2,640.90 | 134.60 | 609.90 | 213.30 |
| 2015-03-28 | 2,579.70 | 116.40 | 590.40 | 209.80 |
| 2014-12-27 | 2,549.10 | 51.80 | 586.50 | 206.50 |
| 2014-09-27 | 2,530.70 | 17.30 | 590.30 | 203.20 |
| 2014-06-28 | 2,476.50 | -1,124.70 | 572.00 | 199.80 |
| 2014-03-29 | 2,469.98 | -1,146.91 | 567.62 | 195.07 |
| 2013-12-28 | 2,457.74 | -1,181.22 | 580.97 | 194.79 |
| 2013-09-28 | 2,492.30 | -1,172.80 | 578.70 | 197.60 |
| 2013-06-29 | 2,458.75 | -136.67 | 607.78 | 195.99 |
| 2013-03-30 | 2,302.80 | -102.16 | 584.15 | 174.45 |
| 2012-12-29 | 2,161.30 | -91.33 | 551.69 | 154.13 |
| 2012-09-29 | 2,002.60 | -73.60 | 508.50 | 131.00 |
| 2012-06-23 | 1,881.15 | 31.70 | 498.27 | 112.75 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Hologic has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Hologic used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.
- It is difficult to establish if Hologic improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Hologic's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Hologic has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
HOLX Health
How is Hologic's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Hologic's finances.
The net worth of a company is the difference between its assets and liabilities.
- Hologic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Hologic's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Hologic Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-30 | 2,159.80 | 3,132.20 | 402.80 |
| 2018-12-29 | 2,394.40 | 3,149.50 | 314.40 |
| 2018-09-29 | 2,428.80 | 3,362.40 | 672.70 |
| 2018-06-30 | 2,449.50 | 3,270.20 | 581.80 |
| 2018-03-31 | 2,445.60 | 3,374.20 | 620.40 |
| 2017-12-30 | 3,194.00 | 3,353.70 | 669.70 |
| 2017-09-30 | 2,784.70 | 3,381.30 | 544.20 |
| 2017-07-01 | 2,865.60 | 3,245.70 | 591.00 |
| 2017-04-01 | 2,797.10 | 3,308.40 | 1,143.00 |
| 2016-12-31 | 2,228.60 | 3,322.90 | 648.50 |
| 2016-09-24 | 2,142.70 | 3,380.20 | 549.40 |
| 2016-06-25 | 2,042.70 | 3,422.20 | 441.90 |
| 2016-03-26 | 2,044.40 | 3,405.70 | 317.20 |
| 2015-12-26 | 2,166.30 | 3,632.40 | 651.40 |
| 2015-09-26 | 2,079.20 | 3,646.20 | 492.00 |
| 2015-06-27 | 2,237.10 | 3,942.30 | 885.80 |
| 2015-03-28 | 2,168.60 | 3,939.80 | 670.90 |
| 2014-12-27 | 2,102.40 | 3,954.80 | 544.00 |
| 2014-09-27 | 2,063.00 | 4,301.80 | 736.10 |
| 2014-06-28 | 2,031.30 | 4,270.50 | 632.50 |
| 2014-03-29 | 1,980.10 | 4,273.46 | 484.52 |
| 2013-12-28 | 1,950.53 | 4,301.77 | 442.49 |
| 2013-09-28 | 1,941.50 | 4,839.40 | 822.50 |
| 2013-06-29 | 2,996.63 | 5,004.67 | 958.44 |
| 2013-03-30 | 2,990.56 | 5,004.70 | 745.00 |
| 2012-12-29 | 2,984.38 | 5,036.02 | 718.47 |
| 2012-09-29 | 2,961.03 | 5,068.87 | 560.43 |
| 2012-06-23 | 3,004.25 | 1,542.15 | 905.08 |
- Hologic's level of debt (145%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has been reduced over the past 5 years (215.7% vs 145% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Whilst loss making Hologic has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
- Whilst loss making Hologic has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 10.8% per year.
Financial health checks
We assess Hologic's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Hologic has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
HOLX Dividends
What is Hologic's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Hologic
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Hologic's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Hologic's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 19 Analyst Estimates (S&P Global) | See Below |
| United States of America Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 24 Stocks | 1.2% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2011 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-09-30 | ||
| 2022-09-30 | ||
| 2021-09-30 | 0.00 | 1.00 |
| 2020-09-30 | 0.00 | 2.00 |
| 2019-09-30 | 0.00 | 2.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Hologic has not reported any payouts.
- Unable to verify if Hologic's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Hologic's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Hologic afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Hologic has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
HOLX Management
CEO
| COMPENSATION | $42,040,142 |
| AGE | 54 |
| TENURE AS CEO | 5.5 years |
CEO Bio
Mr. Stephen P. MacMillan, also known as Steve, has been the Chairman of the Board at Hologic Inc. since June 17, 2015 and its Chief Executive Officer and President since December 9, 2013. Mr. MacMillan served as the Chief Executive Officer of sBioMed, LLC, from October 2012 to December 2013. He served as the Chief Executive Officer and President of Stryker Imaging Corporation. He served as the Chief Executive Officer of Stryker Corporation from January 1, 2005 to February 2012 and served as its President from June 1, 2003 to February 2012. He served as Sector Vice President of Global Specialty Operations at Pharmacia LLC from March 2000 to March 2003, where he was responsible for four of the pharmaceutical company's global businesses. He joined Pharmacia Corporation in 1999. He served as the Chief Operating Officer of the Kalamazoo-based medical supply company from June 1, 2003 to December 31, 2004. He served as the Chief Operating Officer of Stryker Corp. from June 1, 2003 to January 2005. He joined Stryker Corp. in 2003. He began his career with Procter & Gamble in 1985 and later spent 11 years with Johnson & Johnson. He served as Sector Vice President of Global Specialty Operations of Pharmacia & Upjohn, Inc. (“P&U“), a subsidiary of Pharmacia Corp. from December 1999 to March 2000, President of Johnson & Johnson-Merck Consumer Pharmaceuticals from December 1998 to December 1999, Vice President of Marketing and Professional Sales at McNeil Consumer Products, a division of Johnson & Johnson, from March 1997 to December 1998. He has nearly 20 years of experience in the medical industry. He served as the Chairman of Stryker Corp. from January 1, 2010 to February 8, 2012. Mr. MacMillan has been a Director of MDSave Incorporated since August 15, 2013 and Hologic Inc. since December 9, 2013. He has been an Independent Director of Boston Scientific Corporation since April 1, 2015. He serves as a Director of EZ LIFT Rescue Systems, Inc. and Business Leaders for Michigan. He served as a Director of Alere, Inc., Stryker Corporation and Texas Instruments Incorporated. He served as a Director of Stryker Corp. from January 2005 to February 8, 2012. He served as a Director at Alere Inc. since August 2013. He served as a Director of Amersham Biosciences Corporation since 2001. He served as a Director of Texas Instruments Inc. from September 18, 2008 to February 17, 2012. Mr. MacMillan holds a Bachelor of Arts in Economics from Davidson College and is a Graduate of the Harvard Business School Advanced Management Program.
CEO Compensation
- Steve's compensation has increased whilst company is loss making.
- Steve's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Hologic management team in years:
- The tenure for the Hologic management team is about average.
Management Team
Steve MacMillan
Chairman
$42M
54
5.5 yrs
Karleen Oberton
Chief Financial Officer
$3M
48
0.8 yrs
John Griffin
General Counsel
$2M
57
4.3 yrs
Pete Valenti
Division President of Breast & Skeletal Health Solutions
$2M
55
5.1 yrs
Tom West
Division President of Diagnostics Solutions
$2M
54
4.7 yrs
Jay Stein
Co-Founder
$2M
75
33.7 yrs
Michael Watts
Vice President of Investor Relations & Corporate Communications
Ali Bebo
Senior Vice President of Human Resources
49
4.3 yrs
Monica Berthelot
Chief of Staff
0.4 yrs
Mike Kelly
Chief Supply Chain Officer and Corporate VP of Quality Assurance & Regulatory Affairs
1.4 yrs
Board of Directors Tenure
Average tenure and age of the Hologic board of directors in years:
- The average tenure for the Hologic board of directors is less than 3 years, this suggests a new board.
Board of Directors
Steve MacMillan
Chairman
$42M
54
4 yrs
Jay Stein
Co-Founder
$2M
75
11.7 yrs
Sally Crawford
Lead Independent Director
$358K
64
2.4 yrs
Scott Garrett
Independent Director
$278K
68
6.1 yrs
Charles Dockendorff
Independent Director
$274K
64
2.1 yrs
Christiana Stamoulis
Independent Director
$266K
47
7.6 yrs
Amy Wendell
Independent Director
$266K
57
2.5 yrs
Namal Nawana
Independent Director
$265K
47
1.4 yrs
Ludwig Hantson
Independent Director
55
0.6 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 06. Mar 19 | Sell | Peter Valenti | Individual | 01. Mar 19 | 01. Mar 19 | -4,242 | $47.38 | $-200,986 | ||
| 11. Dec 18 | Sell | Peter Valenti | Individual | 07. Dec 18 | 07. Dec 18 | -4,740 | $42.20 | $-200,028 | ||
| 20. Nov 18 | Sell | Allison Bebo | Individual | 16. Nov 18 | 16. Nov 18 | -6,500 | $42.00 | $-273,000 | ||
Management checks
We assess Hologic's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Hologic has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
HOLX News
Simply Wall St News
Does Hologic, Inc.'s (NASDAQ:HOLX) CEO Pay Compare Well With Peers?
When we examined a group of companies with market caps over US$8.0b, we found that their median CEO total compensation was US$11m. … pays Steve MacMillan more than the median CEO remuneration at large companies, in the same market. … We compared the total CEO remuneration paid by Hologic, Inc., and compared it to remuneration at a group of other large companies.
Simply Wall St - – Full articleHologic, Inc. (NASDAQ:HOLX): Time For A Financial Health Check
See our latest analysis for Hologic Does HOLX Produce Much Cash Relative To Its Debt? … Additionally, HOLX has produced US$705m in operating cash flow in the last twelve months, leading to an operating cash to total debt ratio of 22%, meaning that HOLX’s debt is appropriately covered by operating cash. … Next Steps: HOLX’s debt and cash flow levels indicate room for improvement.
Simply Wall St - – Full articleIf You Had Bought Hologic (NASDAQ:HOLX) Stock Five Years Ago, You Could Pocket A 111% Gain Today
By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … So we might find other metrics can better explain the share price movements. … It's quite possible that management are prioritizing revenue growth over EPS growth at the moment.
Simply Wall St - – Full articleHave Insiders Been Selling Hologic, Inc. (NASDAQ:HOLX) Shares?
Hologic Insider Transactions Over The Last Year. … In total, Hologic insiders sold more than they bought over the last year. … We don't gain much confidence from insider selling near the recent share price
Simply Wall St - – Full articleIs Hologic, Inc.'s (NASDAQ:HOLX) Balance Sheet A Threat To Its Future?
the key to their continued success lies in its financial health. … I will provide an overview of Hologic’s financial liquidity and leverage to give you an idea of Hologic’s position to take advantage of potential acquisitions or comfortably endure future downturns. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis
Simply Wall St - – Full articleHologic, Inc.’s (NASDAQ:HOLX) Investment Returns Are Lagging Its Industry
Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … What is Return On Capital Employed (ROCE)? … How Do You Calculate Return On Capital Employed
Simply Wall St - – Full articleHave Insiders Been Buying Hologic, Inc. (NASDAQ:HOLX) Shares?
Hologic Insider Transactions Over The Last Year. … That means that an insider was happy to buy shares at around the current price. … We generally consider it a positive if insiders have been buying on market, even if the share price has increased a bit since then.
Simply Wall St - – Full articleIs Hologic, Inc. (NASDAQ:HOLX) Worth US$42.38 Based On Intrinsic Value?
by taking the expected future cash flows and discounting them to today's value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model
Simply Wall St - – Full articleIs Hologic Inc's (NASDAQ:HOLX) CEO Paid Enough To Stay Motivated?
First, this article will compare CEO compensation with compensation at other large companies. … At the time of writing our data says that Hologic Inc has a market cap of US$11.0b, and is paying total annual CEO compensation of US$11m. … We looked at a group of companies with market capitalizations over US$8.0b and the median CEO compensation was US$11m.
Simply Wall St - – Full articleA Look At The Fair Value Of Hologic Inc (NASDAQ:HOLX)
by estimating the company's future cash flows and discounting them to their present value. … discounted cash flows (DCF). … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model
Simply Wall St - – Full articleHOLX Company Info
Description
Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and analytics products, such as 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, and breast biopsy and biopsy site markers, as well as localization, specimen radiology, ultrasound, and connectivity solutions. In addition, the company offers Selenia Dimensions and 3Dimensions gantries for performing 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D software products; SecurView Workstations; computer aided detection systems; and stereotactic breast biopsy systems. Further, it provides SculpSure, PicoSure, and MonaLisa Touch aesthetic treatment systems; TempSure, a radio frequency energy sourced platform; and MedLite and other products, and system components for medical aesthetics. Additionally, the company offers NovaSure, an endometrial ablation system to treat women suffering from abnormal uterine bleeding; MyoSure surgical products for removal of fibroids, and uterine polyps and other pathology; and Horizon DXA System and Fluoroscan Insight FD skeletal health products. It sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company was founded in 1985 and is headquartered in Marlborough, Massachusetts.
Details
| Name: | Hologic, Inc. |
| HOLX | |
| Exchange: | NasdaqGS |
| Founded: | 1985 |
| $12,823,518,601 | |
| 268,050,138 | |
| Website: | http://www.hologic.com |
| Address: |
Hologic, Inc. 250 Campus Drive, Marlborough, Massachusetts, 01752, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | HOLX | Common Stock | Nasdaq Global Select | US | USD | 01. Mar 1990 | |
| DB | HO1 | Common Stock | Deutsche Boerse AG | DE | EUR | 01. Mar 1990 | |
| LSE | 0J5Q | Common Stock | London Stock Exchange | GB | USD | 01. Mar 1990 | |
| WBAG | HOLX | Common Stock | Wiener Boerse AG | AT | EUR | 01. Mar 1990 | |
| BMV | HOLX * | Common Stock | Bolsa Mexicana de Valores | MX | MXN | 01. Mar 1990 |
Number of employees
Current staff
Industry
| Health Care Equipment | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/15 23:39 |
| End of day share price update: | 2019/06/14 00:00 |
| Last estimates confirmation: | 2019/05/29 |
| Last earnings filing: | 2019/05/01 |
| Last earnings reported: | 2019/03/30 |
| Last annual earnings reported: | 2018/09/29 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
